Elise Lepeltier
elepeltier.bsky.social
Elise Lepeltier
@elepeltier.bsky.social
Reposted by Elise Lepeltier
Registration is open for the 11th SFNano Annual Meeting 2025 that will take place on November 24th – 26th in Lyon, France!
Early bird registration fee until October 15th.
Abstract submission deadline is on September 15th.
For more information and registration:
sfnano2025.univ-lyon1.fr/fr
July 2, 2025 at 5:42 PM
Reposted by Elise Lepeltier
Today it is the MINT Day! A good occasion to share science and good moments together. We are really happy to welcome @aklymchenko.bsky.social to open this beautiful day! Thank you very much again for coming ☺️.
June 12, 2025 at 7:49 AM
Reposted by Elise Lepeltier
Congratulations to Dr. Cécile Doualle for your excellent PhD defense! We are all proud of you!
Congratulations also to your supervisors Dr. Franck Letournel and Dr. Julien Gouju.
May 23, 2025 at 7:46 PM
Reposted by Elise Lepeltier
Calling all researchers working on nanomedicines for crossing biological barriers 📢 Submit your latest research to this exciting themed collection in Nanoscale by 16 May 2025 🗓 Find out more about the collection and how to submit 🔗 blogs.rsc.org/nr/2024/10/2...
March 12, 2025 at 2:30 PM
Reposted by Elise Lepeltier
New article from @labmint.bsky.social by notably Dr. Claire Gazaille and Dr. Guillaume Bastiat:
"Focus on the importance of the process parameters: Temperature cycles and “shock” water addition during the phase inversion process for the formulation of lipid nanoparticles"
February 20, 2025 at 1:07 PM
Reposted by Elise Lepeltier
Nous sommes heureux de vous convier à une journée d’échanges autour des « Formulations Lipidiques pour la Libération d’ARN » le jeudi 3 Avril 2025, à la Faculté de Pharmacie Paris 5.
Le nombre de places est limité. Inscriptions obligatoires en ligne :
framaforms.org/journee-lnp-...
Journée LNP SFNano | Framaforms.org
framaforms.org
February 7, 2025 at 3:30 PM
Congratulations @ZarikianLaura for your great talk at the @SFNano_official annual meeting in @Toulouse : you can be proud of you!
January 30, 2025 at 3:40 PM
Wonderful talk @H_H_Genedy from @LabMint at the @CRSBeNeLuxFr congress to present our PRC @AgenceRecherche NEMESIS project: congratulations ☺️.
January 30, 2025 at 3:40 PM
Excellent talk @H_H_Genedy from @LabMint at #EMJMD_NANOMED Workshop: congratulations !!!
January 30, 2025 at 3:40 PM
Congratulations @MelinaGuerin29 from @LabMint for your excellent presentation at #EMJMD_Nanomed workshop!!!
January 30, 2025 at 3:40 PM
Congratulations Bilel Laoulaou from @RMeS_UMR1229 and from @LabMint for your brilliant talk !! And thank you @AgenceRecherche for the support ! And last but not least: thank you Johann Clouet 😁
January 30, 2025 at 3:40 PM
A beautiful review with @RMeS_UMR1229 in @ADDReditors by notably @H_H_Genedy, Paul Humbert, @Cath_LeVisage, @JeromeGuicheux, @CPassirani and Johann Clouet: first article from our @AgenceRecherche PRC projet “Nemesis”: congratulations to all of you 🥂.

sciencedirect.com/science/articl…
January 30, 2025 at 3:39 PM
It was a great @SFNano_official annual meeting in Montpellier, @LabMint was more than well represented: a big thanks to each of you @MelinaGuerin29, @H_H_Genedy, Bilel Laoulaou and Laura Zarikian 😊🎉
January 30, 2025 at 3:39 PM
Congratulations @H_H_Genedy for your great talk at @SFNano_official annual meeting in Montpellier: well done 👍🏻
January 30, 2025 at 3:39 PM
Tellement honorée, merci infiniment @InstUnivFr
@LabMint @UA_Recherche @UnivAngers @FacSante_Angers
January 30, 2025 at 3:39 PM
Nous sommes à la recherche d’un étudiant pour un stage de Master 2 au @LabMint dont le sujet porte sur la formulation de nanocapsules lipidiques chargées en ARNm pour le traitement de maladies génétiques de l’œil
Si intéressé, envoyez-moi votre CV: elise.lepeltier@univ-angers.fr
January 30, 2025 at 3:39 PM
What a wonderful gift for a chemist 🤩: thank you very much again @Milad_Bar @MelinaGuerin29 @H_H_Genedy @CPassirani @Cooltrail @lautram_no49460 @Lemaire_LabMint @f_franconi, Bilel, Gloria and Laura, I am
really lucky 😍!
January 30, 2025 at 3:39 PM
Merci beaucoup @seb_faure 😊

x.com/seb_faure/stat…
January 30, 2025 at 3:39 PM
Your first poster at @icat_sfr seminar @MelinaGuerin29 and not the last one 😊: congratulations 🎉
January 30, 2025 at 3:39 PM
Oooo I still don’t believe in it 😭. Sometimes life can be very difficult, but life can also be really beautiful. Thank you very much @InstUnivFr ! It is such an honor. And of course, thank you all my team of students 😊.
@UnivAngers @UA_Recherche @InsermGrdOuest @CNRS

x.com/LabMint/status…
January 30, 2025 at 3:39 PM
Today, I was the reviewer of @dasilvalex’s PhD thesis at @umr8612 : congratulations again Alexandre and thank you Sinda Lepêtre and Patrick Couvreur for your invitation 😊.
January 30, 2025 at 3:39 PM
So happy to share with you our last article published in @ACS_Langmuir from @IdlasP’s PhD Thesis founded by @AgenceRecherche with @Feroscan_PSL 🤩!! Thanks all the co-authors, notably @GBastiat, @CPassirani, Prof. Jaouen and Prof. Vessières!

pubs.acs.org/doi/10.1021/ac…
Physicochemical Characterization of Ferrocifen Lipid Nanocapsules: Customized Drug Delivery Systems Guided by the Molecular Structure
Ferrocifens, lipophilic organometallic complexes, comprise a biologically active redox motif [ferrocenyl-ene-p-phenol] which confers very interesting cytotoxic properties to this family. However, because of their highly lipophilic nature, a formulation stage is required before being administered in vivo. In recent decades, ferrocifen lipid nanocapsules (LNCs) have been successfully formulated and have demonstrated anticancer activity on multidrug-resistant cancers in several mice and rat models (glioblastoma, breast cancer, and metastatic melanoma). A recent family of ferrocifens (succinimidoalkyl-ferrociphenols, including P722) appears to be most efficacious on several resistant cancer cell lines, with IC50 values in the nanomolar range together with promising in vivo results on murine ovarian cancer models. As LNCs are composed of an oily core (caprylic/capric triglycerides), modulation of the succinimido-ferrociphenol lipophilicity could be a valuable approach toward improving the drug loading in LNCs. As the drug loading of the diphenol P722 in LNCs was low, it was structurally modified to increase its lipophilicity and thereby the payload in LNCs. Chemical modification led to a series of five succinimido-ferrocifens. Results confirmed that these slight structural modifications led to increased drug loading in LNCs for all ferrocifens, with no reduction of their cytotoxicity on the SKOV3 ovarian cancer cell line. Interestingly, encapsulation of two of the ferrocifens, diester P769 and monophenolic ester (E)-P998, led to the formation of a gel. This was unprecedented behavior, a phenomenon that could be rationalized in terms of the positioning of ferrocifens in LNCs as shown by the decrease of interfacial tension measurements at the water/oil interface. Moreover, these results highlighted the importance of obtaining a gel of this particular motif, in which the acetylated phenolic ring and the succinimidoalkyl moieties are mutually cis relative to the central double bond. Promising perspectives to use these ferrocifen-loaded LNCs to treat glioblastoma could be readily envisaged by local application of the gel in the cavity after tumor resection.
pubs.acs.org
January 30, 2025 at 3:39 PM
Please RT would be appreciated, thank you 😊

x.com/LabMint/status…
January 30, 2025 at 3:38 PM